To evaluate the efficacy, safety and survival of two treatment regimens: Continuous
Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with
prostate cancer. Primary endpoint is time to progression. Fifteen patients will be evaluated.
QoL evaluation is also included.